{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:17:05Z","timestamp":1761808625951},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"DOI":"10.7759\/cureus.48787","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:04:47Z","timestamp":1699967087000},"source":"Crossref","is-referenced-by-count":2,"title":["Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy"],"prefix":"10.7759","author":[{"given":"Nirmal K","family":"Onteddu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sushrutha","family":"Mudupula Vemula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivekananda R","family":"Areddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayabharath","family":"Onteddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejaswi","family":"Mabbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person F","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, et al.. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019, 32:684-700. 10.1038\/s41379-018-0186-4","journal-title":"Mod Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017870","article-title":"Bevacizumab-induced immunoglobulin A vasculitis with nephritis: a case report","volume":"98","author":"Endo Y","year":"2019","unstructured":"Endo Y, Negishi K, Hirayama K, Suzuki H, Shimizu A. Bevacizumab-induced immunoglobulin A vasculitis with nephritis: a case report. Medicine (Baltimore). 2019, 98:e17870. 10.1097\/MD.0000000000017870","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina V","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al.. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358:1129-36. 10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02372-4","article-title":"Chapter 1: evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022","volume":"28","author":"Muto S","year":"2023","unstructured":"Muto S, Matsubara T, Inoue T, et al.. Chapter 1: evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. 2023, 28:1259-97. 10.1007\/s10147-023-02372-4","journal-title":"Int J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-450","article-title":"Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature","volume":"6","author":"Yahata M","year":"2013","unstructured":"Yahata M, Nakaya I, Sakuma T, Sato H, Aoki S, Soma J. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes. 2013, 6:450. 10.1186\/1756-0500-6-450","journal-title":"BMC Res Notes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy","volume":"74","author":"Stokes MB","year":"2008","unstructured":"Stokes MB, Erazo MC, D'Agati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008, 74:1487-91. 10.1038\/ki.2008.256","journal-title":"Kidney Int"},{"key":"ref7","article-title":"A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. (Article in Japanese)","volume":"56","author":"Tomita M","year":"2014","unstructured":"Tomita M, Ochiai M, Shu S, et al.. A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. (Article in Japanese). Nihon Jinzo Gakkai Shi. 2014, 56:612-7.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04532-9","article-title":"Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer","volume":"91","author":"Nihei S","year":"2023","unstructured":"Nihei S, Ikeda T, Aoki T, Murasato F, Yaegashi M, Asahi K, Kudo K. Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer. Cancer Chemother Pharmacol. 2023, 91:427-34. 10.1007\/s00280-023-04532-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.5152\/turkjnephrol.2023.2270357","article-title":"Causes and results of nephrology consultation in oncological diseases: a single-center experience","volume":"32","author":"Tu\u011fcu M","year":"2023","unstructured":"Tu\u011fcu M, Ata\u015f DB. Causes and results of nephrology consultation in oncological diseases: a single-center experience. Turk J Nephrol. 2023, 32:198-202.","journal-title":"Turk J Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey AK","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, et al.. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018, 71:e1-8. 10.1161\/HYPERTENSIONAHA.117.10271","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00504-7","article-title":"Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer","volume":"10","author":"Morimoto M","year":"2021","unstructured":"Morimoto M, Arai T, Matsuura M, Ono Y. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer. CEN Case Rep. 2021, 10:6-11. 10.1007\/s13730-020-00504-7","journal-title":"CEN Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15631","article-title":"Bevacizumab induced proteinuria and hypertension: a comparative analysis of anti-hypertensives utilized within a single institution","volume":"38","author":"Farooqui MW","year":"2020","unstructured":"Farooqui MW, Gustafson N, Patel N, et al.. Bevacizumab induced proteinuria and hypertension: a comparative analysis of anti-hypertensives utilized within a single institution. J Clin Oncol. 2020, 38:e15631. 10.1200\/JCO.2020.38.15_suppl.e15631","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George BA","year":"2007","unstructured":"George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007, 49:e23-9. 10.1053\/j.ajkd.2006.11.024","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/192382-bevacizumab-induced-nephropathy-presenting-as-crescentic-glomerulopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:57Z","timestamp":1707508497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/192382-bevacizumab-induced-nephropathy-presenting-as-crescentic-glomerulopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.48787","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}